Effect of Helicobacter pylori Eradication Therapy on Risk of Hospitalization for a Major Ulcer Event
- 1 March 2011
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 31 (3) , 239-247
Abstract
Study Objective. To compare Helicobacter pylori eradication therapy with antisecretory therapy aloneonthe riskofhospitalization for a major ulcer event.Design. Retrospective, population‐based cohort study.Data Source. The 2000–2006 National Health Insurance database in Taiwan.Patients. A total of 838,176 patients diagnosed with a gastrointestinal ulcer and who filled at least one prescription for antiulcer therapy, either H. pylori eradication therapy (331,364 patients [39.53%])orantisecretory therapy alone (506,812 patients [60.47%]), between January1, 2001, and December 31, 2006.Measurements and Main Results. The primary outcome was hospitalization for a major ulcer event, defined as a gastrointestinal ulcer with hemorrhage and/or perforation. Cox proportional hazards models, adjusted for demographic and clinical characteristics, were used to compare the risk of hospitalization for a major ulcer event between the group receiving H. pylori eradication therapy (triple or quadruple combination therapy that includes an antisecretory agent) and the group receiving antisecretory therapy alone (histamine2‐receptor blocker or proton pump inhibitor). The H. pylori eradication therapy group was divided into initial users (combination therapy received immediately after gastrointestinal ulcer diagnosis) and late users (combination therapy received after antisecretory therapy with time lag≤180 days, 181–365 days, or>365 days from ulcer diagnosis). A secondary analysis was conductedinthe three late H. pylorieradication therapy subgroups to determine if risk of hospitalization for major ulcer events differed by timing of receipt of therapy. Compared with the antisecretory therapy alone group, the H. pylori therapy group (initial users) had a significantly decreased risk of hospitalization for major ulcer events (adjusted hazard ratio [AHR] 0.57, 95% confidence interval [CI] 0.54–0.59, pH. pylori therapy was associated with a higher riskofhospitalization for major ulcer events (time lag 181–365 days, AHR 1.68, 95%CI1.51–1.86, p365 days, AHR 1.74, 95% CI1.67–1.80, pH. pylori therapy within6months(≤180 days) after gastrointestinal ulcers were diagnosed.Conclusion. Helicobacter pyloritherapy given within 6 months of a diagnosis of gastrointestinal ulcer was associated with a reduced risk of hospitalization for major ulcer events. Our findings extend the evidence from clinical trials that report the value ofH. pylori eradication therapy in reducing ulcer recurrence by documenting the real‐world benefit of reducing the risk of hospitalization for major gastrointestinal ulcer events.Keywords
This publication has 23 references indexed in Scilit:
- Helicobacter pylori resistance to metronidazole and clarithromycin in IrelandEuropean Journal of Gastroenterology & Hepatology, 2010
- Eradicating Helicobacter pylori in Peptic Ulcer Disease Reduces Medical Costs in the CommunityHelicobacter, 2008
- Time, change and peptic ulcer disease in Rotherham, UKDigestive and Liver Disease, 2008
- Changing Trends in the Epidemiology and Clinical Outcome of Acute Upper Gastrointestinal Bleeding in a Defined Geographical Area in GreeceJournal of Clinical Gastroenterology, 2008
- Proton-pump inhibitors as a protective treatment for high-risk patients receiving treatment with NSAIDsNature Clinical Practice Rheumatology, 2007
- Causes underlying the birth-cohort phenomenon of peptic ulcer: analysis of mortality data 1911–2000, England and WalesInternational Journal of Epidemiology, 2006
- Current management of peptic ulcer bleedingNature Clinical Practice Gastroenterology & Hepatology, 2006
- Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician‐referred uninvestigated dyspeptic patients in Hong KongAlimentary Pharmacology & Therapeutics, 2005
- Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcerCochrane Database of Systematic Reviews, 2004
- Relationship between the birth cohort pattern of Helicobacter pylori infection and the epidemiology of duodenal ulcerQJM: An International Journal of Medicine, 2002